Products
Pre-made Glenzocimab benchmark antibody ( Fab, anti-GP6 therapeutic antibody, Anti-BDPLT11/GPIV/GPVI Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-247
Pre-Made Glenzocimab biosimilar, Fab, Anti-GP6 Antibody: Anti-BDPLT11/GPIV/GPVI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-247-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-247-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-247-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-247-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Glenzocimab biosimilar, Fab, Anti-GP6 Antibody: Anti-BDPLT11/GPIV/GPVI therapeutic antibody |
| INN Name | Glenzocimab |
| Target | GP6 |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Acticor Biotech |
| Conditions Approved | na |
| Conditions Active | Stroke;COVID-19 |
| Conditions Discontinued | na |
| Development Tech | na |
<